RxDoctor Payments Data

Alpana Senapati

Cardiovascular Disease · Murray, UTNPI 1306103213

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.6%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Abbott at 45.0% of the total.

$3,690in general payments, 2019–2025

Across 85 payments — averaging $43.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$516
  • Astellas Pharma US Inc$410
  • Amgen$391
  • Heartflow, Inc.$176
  • Medtronic$122
  • plus $415 from 10 others

What the payments were for

  • Consulting fees$321%
  • Grants$50014%
  • Travel & lodging$1,11830%
  • Food & beverage$1,94153%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,690 in reported general payments places this provider in the 65th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$77,715
Medicare patients
930
Services billed
1,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$46,533
Repatha SureclickEvolocumab15$11,948
Metoprolol Succinate81$1,277
Atorvastatin Calcium57$913
Rosuvastatin Calcium52$824
Ezetimibe27$794
Furosemide75$506
Carvedilol40$449
Potassium Chloride20$326
Spironolactone26$292
Lisinopril20$265
Losartan Potassium20$217
Amlodipine Besylate31$146
Isosorbide Mononitrate ErIsosorbide Mononitrate17$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$46,53335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →